ARV-825 Demonstrates Antitumor Activity in Gastric Cancer via MYC-Targets and G2M-Checkpoint Signaling Pathways

OBJECTIVE: Suppression of bromodomain and extra terminal (BET) proteins has a bright prospect to treat MYC-driven tumors. Bromodomain containing 4 (BRD4) is one of the BET proteins. ARV-825, consisting of a BRD4 inhibitor conjugated with a cereblon ligand using proteolysis-targeting chimera (PROTAC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Xinmei, Qian, Xiaoqing, Zhang, Zimu, Tao, Yanfang, Li, Zhiheng, Zhang, Qian, Liang, Hui, Li, Xiaolu, Xie, Yi, Zhuo, Ran, Chen, Yanling, Jiang, You, Cao, Haibo, Niu, Jiaqi, Xue, Cuili, Ni, Jian, Pan, Jian, Cui, Daxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559897/
https://www.ncbi.nlm.nih.gov/pubmed/34733788
http://dx.doi.org/10.3389/fonc.2021.753119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8559897/
https://www.ncbi.nlm.nih.gov/pubmed/34733788
http://dx.doi.org/10.3389/fonc.2021.753119

Ejemplares similares